Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Lipscombe
Date of last notice	21 November 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	*Direct* Dr Richard John Lipscombe *Indirect* Dr Richard John Lipscombe <The LUK A/C> Dr Lipscombe is the trustee and a beneficiary of the trust Bjouxz Pty Ltd <The Loz Superannuation Fund> Dr Lipscombe is beneficiary of the superannuation fund and sole director and shareholder of the trustee.
Date of change	6 June 2025

+ See chapter 19 for defined terms.

No. of securities held prior to change	*Direct* 6,530,536 Shares *Indirect* 9,886,590 Shares 1,000,000 Tranche A Executive Options 800,000 Tranche B Executive Options 800,000 Tranche C Executive Options
Class	(a) Ordinary Fully Paid Shares (b) Options - PIQOPT10
Number acquired	*Direct* (a) 324,324 Ordinary Fully Paid Shares (b) 162,162 Options - PIQOPT10 *Indirect* (a) 405,406 Ordinary Fully Paid Shares (b) 202,703 Options - PIQOPT10
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Cash consideration (b) Director Placement participants will receive 1 option for every 2 New Shares issued, exercisable at A$0.50, expiring 31 May 2026, with nil cash consideration
No. of securities held after change	*Direct* 6,854,860 Shares 162,162 Options - PIQOPT10 *Indirect* 10,291,996 Shares 1,000,000 Tranche A Executive Options 800,000 Tranche B Executive Options 800,000 Tranche C Executive Options 202,703 Options - PIQOPT10
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Fully Paid Shares and Options following receipt of Shareholder approval at the Extraordinary General Meeting held on 30 May 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder **(if issued securities)**	Not applicable

Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul House
Date of last notice	24 October 2022

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Baljuna Capital Pty Ltd Mr House is a Shareholder and Director of the entity
Date of change	6 June 2025
No. of securities held prior to change	*Direct* 343,864 Shares *Indirect* 692,647 Shares
Class	(a) Ordinary Fully Paid Shares (b) Options - PIQOPT10
Number acquired	(a) 135,135 Ordinary Fully Paid Shares (b) 67,567 Options - PIQOPT10
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Cash consideration (b) Director Placement participants will receive 1 option for every 2 New Shares issued, exercisable at A$0.50, expiring 31 May 2026, with nil cash consideration
No. of securities held after change	*Direct* 343,864 Shares *Indirect* 827,782Shares 67,567 Options - PIQOPT10
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Fully Paid Shares and Options following receipt of Shareholder approval at the Extraordinary General Meeting held on 30 May 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder **(if issued securities)**	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No

+ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Neville Gardiner
Date of last notice	18 June 2024

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Gardiner Family Superannuation Fund Mr Gardiner is joint trustee and a beneficiary of the superannuation fund Fertilus Pty Ltd ATF the Gardiner Family Trust Mr Gardiner is director and shareholder of the trustee and a beneficiary of the trust.
Date of change	6 June 2025

No. of securities held prior to change	*Direct* Nil *Indirect* 117,647 Shares 250,000 Unquoted options exercisable at $1.32 per option on or before 24 November 2025 (Director C Options) 250,000 Unquoted options exercisable at $1.76 per option on or before 24 November 2026 (Director D Options)
Class	(a) Ordinary Fully Paid Shares (b) Options - PIQOPT10
Number acquired	(a) 81,081 Ordinary Fully Paid Shares (b) 40,540 Options - PIQOPT10
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Cash consideration (b) Director Placement participants will receive 1 option for every 2 New Shares issued, exercisable at A$0.50, expiring 31 May 2026, with nil cash consideration.
No. of securities held after change	*Direct* Nil *Indirect* 198,728 Shares 250,000 Unquoted options exercisable at $1.32 per option on or before 24 November 2025 (Director C Options) 250,000 Unquoted options exercisable at $1.76 per option on or before 24 November 2026 (Director D Options) 40,540 Options - PIQOPT10
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Fully Paid Shares and Options following receipt of Shareholder approval at the Extraordinary General Meeting held on 30 May 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder **(if issued securities)**	Not applicable

Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Proteomics International Laboratories Ltd
ABN	78 169 979 971

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Aaron Brinkworth
Date of last notice	Not applicable

Part 1 - Change of director's relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Aaron Brinkworth
Date of change	6 June 2025
No. of securities held prior to change	*Direct* Nil *Indirect* Nil
Class	(a) Ordinary Fully Paid Shares (b) Options - PIQOPT10
Number acquired	(a) 135,135 Ordinary Fully Paid Shares (b) 67,567 Options - PIQOPT10
Number disposed	Nil

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(a) Cash consideration (b) Director Placement participants will receive 1 option for every 2 New Shares issued, exercisable at A$0.50, expiring 31 May 2026, with nil cash consideration
No. of securities held after change	*Direct* 135,135 Shares 67,567 Options - PIQOPT10 *Indirect* Nil
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Ordinary Fully Paid Shares and Options following receipt of Shareholder approval at the Extraordinary General Meeting held on 30 May 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Not applicable
Nature of interest	Not applicable
Name of registered holder (if issued securities)	Not applicable
Date of change	Not applicable
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Not applicable
Interest acquired	Not applicable
Interest disposed	Not applicable
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Not applicable
Interest after change	Not applicable

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No

+ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

+ See chapter 19 for defined terms.